IQV:NYE-IQVIA Holdings Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 208.1

Change

0.00 (0.00)%

Market Cap

USD 37.99B

Volume

1.11M

Analyst Target

USD 184.17
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.49 (-0.18%)

USD 197.82B
A Agilent Technologies Inc

+0.42 (+0.29%)

USD 41.65B
LH Laboratory Corporation of Amer..

+0.93 (+0.43%)

USD 18.06B
DGX Quest Diagnostics Incorporated

-1.34 (-0.88%)

USD 17.19B
QGEN Qiagen NV

+0.03 (+0.07%)

USD 10.05B
CRL Charles River Laboratories

+1.15 (+0.61%)

USD 9.79B
VNRX Volitionrx Ltd

+0.12 (+16.21%)

USD 0.06B
ENZ Enzo Biochem Inc

+0.01 (+0.88%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-2.31 (-0.38%)

N/A
MTD Mettler-Toledo International I..

-10.58 (-0.72%)

N/A

ETFs Containing IQV

EKG First Trust Nasdaq Lux Di.. 7.19 % 0.00 %

+0.22 (+-0.52%)

USD 2.53M
RSPH Invesco S&P 500® Equal.. 1.76 % 0.00 %

+0.09 (+-0.52%)

USD 1.02B
HEAL:SW iShares Healthcare Innova.. 1.66 % 0.00 %

-0.04 (-0.52%)

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

+1.02 (+-0.52%)

USD 0.45B
GNRX 0.00 % 0.55 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+1.29 (+-0.52%)

USD 7.60B
PBI Pitney Bowes Inc 0.00 % 0.79 %

+0.11 (+-0.52%)

USD 1.22B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.02 (+-0.52%)

CAD 0.05B
VNMC 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.06% 38% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.06% 38% F 16% F
Trailing 12 Months  
Capital Gain -4.02% 38% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.02% 38% F 21% F
Trailing 5 Years  
Capital Gain 31.26% 42% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.26% 42% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 14.52% 62% D 79% B-
Dividend Return 14.52% 62% D 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.12% 62% D 36% F
Risk Adjusted Return 49.86% 62% D 71% C-
Market Capitalization 37.99B 85% B 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.